Sarepta Therapeutics, Inc.
    SEC Filings

    |
    |

    All SEC filings by Sarepta Therapeutics, Inc. (SRPT) — annual and quarterly reports, current reports, registrations, proxies and ownership forms, updated in real time.

    Financials

    10-QQuarterly reportView DiffAug 5, 2026
    10-QQuarterly reportView DiffMay 6, 2026
    ARSAnnual report to shareholdersApr 24, 2026
    10-KAnnual reportView DiffMar 2, 2026
    10-QQuarterly reportView DiffNov 6, 2025
    10-QQuarterly reportView DiffAug 6, 2025
    10-QQuarterly reportView DiffMay 6, 2025
    ARSAnnual report to shareholdersApr 24, 2025
    10-KAnnual reportView DiffFeb 28, 2025
    10-QQuarterly reportView DiffNov 6, 2024

    Events

    8-KSarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate DevelopmentsAug 5, 2026
    8-KSarepta Therapeutics Appoints Michael Severino, M.d., Chief Executive OfficerJul 27, 2026
    8-KCurrent reportJun 4, 2026
    8-KSarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate DevelopmentsMay 6, 2026
    8-KDeparture of Directors or Certain OfficersFeb 25, 2026
    8-KSarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate DevelopmentsFeb 25, 2026
    8-KSarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product RevenuesJan 12, 2026
    8-KEntry Into a Material Definitive AgreementDec 19, 2025
    8-KSarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes Due 2027Dec 11, 2025
    8-KDeparture of Directors or Certain OfficersDec 8, 2025

    Registrations and Prospectuses

    S-8Registration of securities for employeesJul 28, 2026
    S-8Registration of securities for employeesJun 4, 2026
    S-8Registration of securities for employeesAug 6, 2025
    S-3ASRAutomatic shelf registrationMar 3, 2025
    S-8Registration of securities for employeesAug 7, 2024
    S-8 POSRegistration of securities for employees (post-effective amendment)Mar 28, 2024
    S-8 POSRegistration of securities for employees (post-effective amendment)Mar 28, 2024
    S-8 POSRegistration of securities for employees (post-effective amendment)Mar 28, 2024
    S-8 POSRegistration of securities for employees (post-effective amendment)Mar 28, 2024
    S-8Registration of securities for employeesAug 2, 2023

    Proxies

    DEFA14AAdditional proxy soliciting materialsApr 24, 2026
    DEF 14ADefinitive proxyView DiffApr 24, 2026
    DEFA14AAdditional proxy soliciting materialsApr 24, 2025
    DEF 14ADefinitive proxyView DiffApr 24, 2025
    DEF 14ADefinitive proxyView DiffApr 24, 2024
    DEFA14AAdditional proxy soliciting materialsApr 24, 2024
    DEFA14AAdditional proxy soliciting materialsApr 24, 2023
    DEF 14ADefinitive proxyView DiffApr 24, 2023
    DEF 14ADefinitive proxyView DiffApr 25, 2022
    DEFA14AAdditional proxy soliciting materialsApr 20, 2021

    Other

    UPLOADLetter from SECApr 16, 2020
    CORRESPCorrespondence with SECApr 15, 2020
    UPLOADLetter from SECApr 13, 2020
    CT ORDERConfidential treatment orderNov 9, 2018
    CT ORDERConfidential treatment orderSep 12, 2017
    CT ORDERConfidential treatment orderJan 19, 2017
    CT ORDERConfidential treatment orderOct 4, 2016
    EFFECTNotice of effectivenessMay 5, 2015
    CORRESPCorrespondence with SECMay 4, 2015
    UPLOADLetter from SECApr 29, 2015

    Ownership

    13F-HRQuarterly holdings report by institutional managerAug 13, 2026
    SC 13G/ABeneficial ownership reportAug 13, 2026
    SC 13GBeneficial ownership reportAug 7, 2026
    SC 13G/ABeneficial ownership reportJul 31, 2026
    SC 13G/ABeneficial ownership reportJul 30, 2026
    4Severino MichaelJul 29, 2026
    3Severino MichaelJul 29, 2026
    4Boor Kathryn JeanJun 5, 2026
    4Mayo StephenJun 5, 2026
    4Wigzell Hans Lennart RudolfJun 5, 2026